Skip to main content
. Author manuscript; available in PMC: 2016 Nov 15.
Published in final edited form as: Gynecol Oncol. 2010 Apr 2;117(3):497–504. doi: 10.1016/j.ygyno.2010.02.021

Table 5.

National Cancer Institute common toxicity criteria of adverse events34.

Adverse event Grade 1 Grade 2 Grade 3 Grade 4
Hypertension Prehypertension (systolic BP 120–139 mm Hg or diastolic BP 80–89 mm Hg) Stage 1 hypertension (systolic BP 140–159 mm Hg or diastolic BP 90–99 mm Hg); medical intervention indicated; recurrent or persistent (≥24 h); symptomatic increase by >20 mm Hg (diastolic) or to >140/90 mm Hg if previously WNL; monotherapy indicated. Stage 2 hypertension (systolic BP ≥160 mm Hg or diastolic BP ≥100 mm Hg); medical intervention indicated; more than one drug or more intensive therapy than previously used indicated Life-threatening consequences (e.g., malignant hypertension, transient or permanent neurologic deficit, hypertensive crisis); urgent intervention indicated
Proteinuria Urinary protein <1.0 g/24 h; UPCR <1 Urinary protein 1.0–3.5 g/24 h; UPCR 1–3.5 Urinary protein >3.5 g/24 h; UPCR >3.5 Nephrotic syndrome

BP=blood pressure; WNL=within normal limits; UPCR=urine protein to creatinine ratio.